Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

Colon Cancer Clinical Trial

— COnCERTO  

Official title:

Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy : A Randomized Phase III Trial - COnCERTO (French 01-18)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06107920
• Other study ID #: 2019/0407/HP
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 2024
• Est. completion date: January 2031

Study information

• Verified date: October 2023
• Source: University Hospital, Rouen
• Contact: Valérie Bridoux
• Phone: 0232881347
• Email: valerie.bridoux[@]chu-rouen.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to determine whether chemotherapy prior to tumor removal (neoadjuvant chemotherapy), in patients undergoing treatment for colon cancer in occlusion (CCO), would improve the rate of patients able to benefit from "optimal" treatment, i.e. complete treatment (including all neoadjuvant and adjuvant chemotherapy cures).

This new strategy, which would combine chemotherapy before surgery and possibly post-operatively (depending on tumor analysis), could improve the prognosis of occluded colon cancers by treating circulating micrometastases and/or inducing a reduction in tumor size, thereby increasing the rate of complete resection.

Description:

In France, for patients admitted for an obstructive colon cancer, surgery is the preferred strategy. Primary diverting stoma is associated with low morbidity, and low 30-day mortality. Primary diverting stoma is not a major surgical undertaken, is effective to relief bowel obstruction, enables optimization of the patient's condition, allows adequate oncological staging and secondary elective colectomy. This strategy is actually recommended by the French and European Guidelines in patients with left-sided obstructive colon cancer and may be an option in patients with right-sided obstructive colon cancer, especially in those at high risk of postoperative complications

Urgent surgery for obstructive colon cancer is associated with increased risk of postoperative morbidity, mortality and permanent stoma rates as it is generally performed in elderly patients with poor medical condition or in patients with severe comorbidities. Moreover, obstructive colon cancers are diagnosed at locally advanced (T4) or metastatic stage and, at equal tumour stage, obstruction itself negatively impacts oncological outcomes in colon cancer patients. Among the several factors that may explain poor oncological outcomes of OCC, the absence of adjuvant chemotherapy may play an important role.

Adjuvant chemotherapy is the standard of care for patients undergoing curative resection for a stage III CC. For those with MSS high-risk stage II CC, adjuvant treatment is still a matter of debate. However, in the particular setting of MSS stage II obstructing CC, adjuvant chemotherapy may improve oncological outcomes. Because of high postoperative morbidity and patients' medical conditions, up to 37% of OCC patients for whom adjuvant systemic chemotherapy is considered appropriate do not receive this treatment. It is our hypothesis that the initiation of chemotherapy before resection of the primary tumour in a perioperative setting in patients with non-metastatic OLCC and for whom the obstruction has been relieved by a colostomy may allow to treat a higher proportion of patients with a full curative therapeutic sequence (including resection and chemotherapy if needed).

Randomized phase II-III trials have demonstrated the feasibility (tolerance, postoperative morbidity) and the efficacy (tumor downstaging, tumor downsizing, histological regression, higher R0 resection rate) of neoadjuvant FOLFOX or CAPOX chemotherapy in uncomplicated colon cancer with a trend towards an improvement of DFS. Data of these studies led the French Oncological Authorities to accept neoadjuvant chemotherapy in a perioperative setting as a therapeutic option in patients with locally advanced colon cancer (TNCD 21/01/2019, chapter 3, Cancer du colon non métastatique (p10): "Neo-adjuvant chemotherapy may be considered for locally advanced tumors deemed unresectable or at the limit of resectability (expert opinion)"; "it is possible to perform an upstream stoma before starting chemotherapy ("neo-adjuvant") and then a re-intervention aimed at exeresis (expert opinion). This treatment option should be discussed at the preoperative multidisciplinary consultation meeting if a T4 tumor is suspected during the preoperative workup."

The authors concluded that neoadjuvant chemotherapy using FOLFOX was feasible and might be a treatment option for patients with obstructive colon cancer for whom the obstruction has been relieved by a definctioning stoma. Further large-scale studies are warranted to confirm the present findings. This is exactly what COnCERTO trial aims to determine.

It is our hypothesis that the initiation of neoadjuvant chemotherapy in a perioperative setting in patients with non-metastatic MSS/pMMR Obstructive Colon Cancer (OCC) and for whom the obstruction has been relieved by a stoma may improve the compliance of the treatment and thus may allow to increase the rate of patients receiving the full curative therapeutic sequence according to the guidelines defined as following:

Resection of the primary tumor WITH:

• Low-risk stage II: NO CHEMOTHERAPY

• High-risk stage II: CHEMOTHERAPY AT INVESTIGATOR'S DISCRETION

• Stage III pT1-T3N1: CAPOX (3 months) or FOLFOX (6 months)

• Stage III pT4 and/or N2: FOLFOX (6 months) MSS High-risk stage II are defined as following: No microsatellite instability and presence of vascular emboli, perinervous or lymphatic invasion, poor differentiation, <12 harvested lymph nodes, perforation).

In addition, once OCC are known to have poor prognosis compared to their non-complicated counterparts, neoadjuvant chemotherapy (before resection of the primary) may improve prognosis of these patients by treating circulating micrometastases or by inducing tumor down-staging and thus improving the R0 resection rate.

We thus designed a randomized phase III trial aiming to assess whether FOLFOX or CAPOX neoadjuvant chemotherapy in a perioperative setting may increase the rate of full curative therapeutic sequence in patients with MSS/pMMR OCC first treated by a defunctionning stoma (figure 5).

Demonstrating the positive impact on complicance to the full curative therapic strategy of perioperative chemotherapy in patients with OCC treated by defunctioning stoma, may change medical practices at a national and international level and may lead to a new standard of care. OCC is a major public health issue with no improvement in prognosis during the past decade. By improving the compliance of treatment of patients with OCC, the present study will ensure public health and economic benefits

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 232
• Est. completion date: January 2031
• Est. primary completion date: January 2031
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• ECOG performance status 0 or 1

• Patients with obstructive colon cancer treated by defunctioning stoma

• Pathologically confirmed adenocarcinoma (=10 cm from the anal verge- left transverse colon) - MSS/pMMR (microsatellites stable primary tumor) status

• Patient requiring colectomy

• Laboratory data including : White blood cell count = 3.109 /L with Neutrophils = 1,5.109 / L, Platelet count = 100.109 / L, Hemoglobin = 9 g/dL (5,6 mmol/L), Total bilirubin = 1,5 x ULN (upper limit of normal), ASAT and ALAT = 2,5 x ULN, Alkaline phosphatase = 1,5 x ULN, Serum creatinine = 1,5 x ULN (performed 10-15 days prior to randomization).

• Non metastatic colon cancer (lung, liver, peritoneal) on thoracic-abdomino-pelvis CT scan

• Absence of synchronous colorectal cancer

• No prior chemotherapy or abdominal or pelvic irradiation

• No history of colorectal cancer

• No serious medical co-morbidity : uncontrolled inflammatory bowel disease, uncontrolled angina, recent [within the past 6 months] myocardial infarction, or another serious medical condition, judged to compromise ability to tolerate chemotherapy and/or surgery

• Women of childbearing potential with effective contraception will be required during chemotherapy treatment and for 6 months after cessation of chemotherapy treatment and a negative blood pregnancy test by beta-HCG at inclusion.

• Women surgically sterile (absence of ovaries and/or uterus)

• Postmenopausal women: confirmation diagnostic (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit)

• For men participating in the study, contraception is required during the trial and for 6 months after stopping chemotherapy treatment.

• Patient able to comply with the study protocol, in the investigator's judgment

• Patient affiliated with, or beneficiary of a social security (national health insurance) category

• Person informed and having signed his consent

Exclusion Criteria:

• Contraindication to colectomy and/or anesthesia

• Rectal cancer located within 10 cm of the anal verge by endoscopy or under the peritoneal reflection at surgery

• Patient having received radiation therapy prior to surgery

• Metastatic spread at baseline assessment (lung, liver, peritoneal)

• History or current evidence on physical examination of central nervous system disease or; Peripheral neuropathy = grade 1

• Contraindication to study neoadjuvant chemotherapy treatments

• Presence of inflammatory bowel disease, HNPCC syndrome or polyposis Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 months, or high risk of uncontrolled arrhythmia

• Uracilemia = 150 ng/ml (suggestive of complete DPD deficiency)

• Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent

• Any significant disease, which, in the investigator's opinion, would exclude the patient from the study.

• Patient is a pregnant (positive blood pregnancy test) or breastfeeding (lactating) woman or intending to become pregnant during the study and for at least 6 months after the treatment termination

• Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)

• Simultaneous participation in another interventional research

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms

Intervention

Drug:
• Neoadjuvant chemotherapy
Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Rouen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the success of a full curative therapeutic	The treatment is complete if all the chemotherapy treatments (adjuvant for arm I / neoadjuvant and adjuvant for arm II) is done.	36 months
Secondary	Neoadjuvant chemotherapy Adverse events	Adverse events (grade 3,4 and 5 toxicity) related to neoadjuvant chemotherapy including those related to the primary tumor	36 months
Secondary	adjuvant chemotherapy adverse events	Adverse events (grade 3, 4 and 5 toxicity) related to adjuvant chemotherapy including those related to the primary tumor	36 months
Secondary	Number of cycles administered of neoadjuvant chemotherapy	Number of cycles administered of neoadjuvant chemotherapy	36 months
Secondary	Rate of primary tumour resection	Rate of primary tumour resection	36 months
Secondary	Quality and completeness of the surgical excision	number of lymph nodes examined, completeness of the mesocolon, margins	36 months
Secondary	Overall morbidity according to the Dindo classification	according to the Dindo classification	at 90 days postoperatively.
Secondary	Overall mortality	mortality without relapse	at 3 years and mortality without stoma at 3 years.
Secondary	Quality of life evaluated using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC	using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC	at J0, week5 (FOLFOX)/week7 (CAPOX), week9 (FOLFOX) and every 6 months a year